Frailty, sarcopenia and diabetic kidney disease: where do we stand?

The current state and development trends of frailty research in diabetic patients: a bibliometric analysis

Background

Diabetes mellitus is a global public health issue, often leading to organ damage, complications, and disabilities. Frailty is an age-related syndrome characterized by reduced physiological reserve and increased vulnerability to stressors, significantly affecting the prognosis of older diabetic patients. The prevalence of frailty is notably higher in older adults with diabetes than in those without. Therefore, a bibliometric analysis of research on diabetes-related frailty can provide deeper insights into the current state of this field and inform future research directions.

Methods

This study retrieved English-language publications on diabetes-related frailty from the Web of Science Core Collection (WOS) database, covering the period from 2005 to 2023. A total of 403 articles were included in the analysis. Statistical analysis and data visualization were conducted using Microsoft Excel, R Studio, VOS viewer, and Cite Space 6.3.R1. The analysis emphasized journals, authors, keywords, country collaborations, institutional collaborations, and references to elucidate trends and knowledge structures within the field of diabetes-related frailty research.

Results

The number of publications on diabetes-related frailty has been steadily increasing each year, with research predominantly focused in developed countries, particularly the United States and Europe. The University of London has emerged as the institution with the highest volume of publications, while Alan J. Sinclair has been recognized as a significant contributor to this field. Key research hotspots include the complications associated with diabetes-related frailty, epidemiology, and quality of life. Additionally, a timeline analysis of references suggests that diabetic nephropathy is currently at the forefront of research in this area.

Conclusion

This comprehensive bibliometric analysis of diabetes-related frailty research underscores the necessity for improved international collaboration to further investigate the mechanisms underlying diabetes-related frailty and to devise more effective prevention and treatment strategies. Future research should emphasize the relationship between diabetic nephropathy and frailty, as well as the development of personalized intervention programs tailored for frail diabetic patients.

The Effect of Carnosine Supplementation on Musculoskeletal Health in Adults with Prediabetes and Type 2 Diabetes: A Secondary Analysis of a Randomized Controlled Trial

BACKGROUND/OBJECTIVES

Type 2 diabetes (T2D) is associated with an increased risk of adverse musculoskeletal outcomes likely due to heightened chronic inflammation, oxidative stress, and advanced glycation end-products (AGE). Carnosine has been shown to have anti-inflammatory, anti-oxidative, and anti-AGE properties. However, no clinical trials have examined the impact of carnosine on musculoskeletal health in adults with prediabetes or T2D.

METHODS

In a randomized, double-blind clinical trial, 49 participants with prediabetes or T2D and without existing musculoskeletal conditions were assigned to receive either 2 g/day carnosine or matching placebo for 14 weeks. Whole-body dual-energy X-ray absorptiometry (DXA) was used to assess body composition, and peripheral quantitative computed tomography (pQCT) was used to assess bone health at the distal and proximal tibia.

RESULTS

Forty-three participants completed this study. Carnosine supplementation had no effect on change in hand grip strength (HGS) or upper-limb relative strength (HGS/lean mass) versus placebo. Change in appendicular lean mass, percentage of body fat, visceral fat area, proximal tibial cortical volumetric bone mineral density (vBMD), distal tibial trabecular vBMD, and stress-strain index did not differ with carnosine compared to placebo. Fourteen weeks of carnosine supplementation did not improve muscle strength, body composition, or bone health in adults with prediabetes or T2D.

CONCLUSIONS

Carnosine supplementation may not be an effective approach for improving musculoskeletal health in adults with prediabetes and T2D without musculoskeletal conditions. However, appropriately powered trials with longer duration are warranted to confirm our findings. The trial was registered at clinicaltrials.gov (NCT02917928).

Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review

Menopause is accompanied by several metabolic adaptations, which are related to insulin resistance, increased total body fat mass, and central abdominal fat accumulation, predisposing women to type 2 diabetes mellitus (T2DM) development. Metabolic syndrome has a high prevalence in postmenopausal women, indicating the loss of estrogen protection on metabolic and cardiovascular health. Moreover, earlier age at menopause has been related to increased risk of T2DM. Menopausal hormone therapy (MHT) has favorable results in glucose metabolism. Indeed, it reduces the risk of T2DM in women without this condition and improves glycemic control in women with T2DM. Before MHT initiation in women with clinical indications, it is imperative to assess their cardiovascular disease (CVD) risk, using official electronic algorithms for score calculation. The latter will determine regimen, dose, and administration route of MHT. Oral estrogens are preferable in women with low CVD risk, while transdermal administration is indicated in those with moderate and high CVD risk, as the risk of stroke and venous thromboembolism (VTE) is increased with oral administration. Oral 17β-estradiol is usually preferred in women with T2DM, as this route has more beneficial effects on glucose metabolism. Oral estrogens are also suggested in perimenopausal or recently postmenopausal women with low CVD risk. Although oral estrogens have favorable effects when indicated, the risk of VTE or stroke should always be considered. Micronized progesterone, dydrogesterone, and transdermal norethisterone are the progestogens used in postmenopausal women with T2DM and intact uterus. MHT should not be initiated in women > 60 years or > 10 years in menopause, as there is an increased thromboembolic risk in women with established atherosclerosis and no additional cardiovascular benefit in women without atherosclerosis. In conclusion, MHT administration in postmenopausal women with T2DM can be safe and effective as long as the therapeutic regimen has been properly selected according to their cardiovascular, metabolic, and fracture risk.

Sarcopenia and Tuberculosis: Is There Any Connection?

BACKGROUND

Tuberculosis (TB) infection is a life-threatening infection caused by certain bacteria belonging to the Mycobacterium tuberculosis complex. More than 10 million subjects are newly sick from this infection every year globally. At the same time, TB is quite prevalent among subjects who come from lower socioeconomic layers of general population, and marginalized sections and areas. Sarcopenia is a muscle disease that derives from adverse muscle alterations and is related to the loss of muscle strength and mass. It is a major medical issue due to its increased adverse outcomes including falls, functional decline, frailty, hospitalizations, increased mortality, and healthcare costs.

METHODS

This study examined the potential interplay between the TB infection and sarcopenia through conducting a non-systematic review of the current literature.

RESULTS

It has been recorded that the prevalence of sarcopenia among TB survivors is high, whilst the danger of TB among the elderly increases with sarcopenia and physical inactivity. Nevertheless, sufficient protein and total energy intake are associated with a low risk of sarcopenia in TB survivors.

CONCLUSIONS

Further studies are needed to validate these findings and shed more light on the upcoming different aspects of this intriguing association.

Decreased Physical and Daily Living Activities in Patients with Peripheral Arterial Disease on Hemodialysis

Decreased physical activity and activities of daily living (ADL) in patients on hemodialysis (HD) are associated with a poor prognosis. Additionally, comorbid peripheral arterial disease is associated with further deterioration. We conducted a cross-sectional study of ADL difficulty and life-space assessment (LSA) in three groups of patients on hemodialysis according to their ankle-brachial index (ABI) values. The 164 patients were divided into ABI Low (ABI < 0.9), Normal (0.9 ≤ ABI < 1.3), and High (1.3 ≤ ABI) groups, and compared using analysis of covariance with LSA and ADL difficulty adjusted for age. The Kihon checklist (KCL) was used to assess the presence of frailty. The LSA was lower in the Low group than in the High group (F = 3.192, p = 0.044). Similarly, the ADL difficulty was significantly lower in the Low group than in the Normal group (F = 3.659, p = 0.028). In the Low group, the proportion of patients with frailty was 47.1% and KCL physical was significantly lower, indicating that patients on HD with a lower ABI had a higher prevalence of frailty and lower LSA and ADL difficulty. In conclusion, patients on HD with decreased ABI values most likely exhibit decline in physical activity and ADL due to frailty and claudication.